Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia

被引：12

作者：

Messinger, Yoav ^{[1
]}

Boklan, Jessica ^{[2
]}

Goldberg, John ^{[3
]}

DuBois, Steven G. ^{[4
,5
,10
,11
]}

Oesterheld, Javier ^{[6
]}

Abla, Oussama ^{[7
]}

Martin, Alissa ^{[8
,9
]}

Weinstein, Joanna ^{[8
,9
]}

Hijiya, Nobuko ^{[8
,9
]}

机构：

[1] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA

[2] Phoenix Childrens Hosp, Phoenix, AZ USA

[3] Univ Miami, Miller Sch Med, Div Pediat Hematol Oncol, Miami, FL 33136 USA

[4] UCSF Sch Med, Dept Pediat, San Francisco, CA USA

[5] UCSF Benioff Childrens Hosp, San Francisco, CA USA

[6] Carolinas Med Ctr, Levine Childrens Hosp, Charlotte, NC 28203 USA

[7] Univ Toronto, Hosp Sick Children, Div Hematol Oncol, Toronto, ON, Canada

[8] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol Stem Cell Transplant, Evanston, IL 60208 USA

[9] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Evanston, IL 60208 USA

[10] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA

[11] Harvard Med Sch, Boston, MA USA

来源：

PEDIATRIC HEMATOLOGY AND ONCOLOGY | 2017年 / 34卷 / 04期

关键词：

Acute myeloid leukemia; clofarabine; pediatric oncology; relapse; refractory; ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC-PATIENTS; PHASE-I; OLDER PATIENTS; TRIAL; CHILDREN; THERAPY; AML; DAUNORUBICIN; CYTARABINE;

D O I：

10.1080/08880018.2017.1360970

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Relapsed/refractory acute myeloid leukemia (AML) has an extremely poor prognosis. We describe 17 children and adolescents with relapsed/refractory AML who received clofarabine, cyclophosphamide, and etoposide. Seven patients (41%) responded: 4 with a complete response (CR); 1 with CR with incomplete platelet recovery; and 2 with a partial response. Additionally, 4 developed hypocellular marrow without evidence of leukemia; 5 patients had resistant disease; and 1 suffered early toxic death. After further therapy including transplantation, 4 patients (24%) are alive without evidence of disease at a median of 60months. This anthracycline-free regimen may be studied for relapsed or refractory AML, but due to the high risk of marrow aplasia reduced doses of clofarabine and cyclophosphamide should be used.

引用

页码：187 / 198

页数：12

共 21 条

[1] Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias [J].

Abd Elmoneim, Abeer ;

Gore, Lia ;

Ricklis, Rebecca M. ;

Boklan, Jessica ;

Cooper, Todd ;

Narendran, Aru ;

Rolla, Katherine ;

Scott, Tammy ;

Arceci, Robert J. .

PEDIATRIC BLOOD & CANCER, 2012, 59 (07) :1252-1258

[2] A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia [J].

Burnett, A. K. ;

Russell, N. H. ;

Hills, R. K. ;

Kell, J. ;

Nielsen, O. J. ;

Dennis, M. ;

Cahalin, P. ;

Pocock, C. ;

Ali, S. ;

Burns, S. ;

Freeman, S. ;

Milligan, D. ;

Clark, R. E. .

LEUKEMIA, 2017, 31 (02) :310-317

[3] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[4]

Cooper T, 2012, ASH ANN M, V120, P3604

[5] Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial [J].

Faderl, Stefan ;

Wetzler, Meir ;

Rizzieri, David ;

Schiller, Gary ;

Jagasia, Madan ;

Stuart, Robert ;

Ganguly, Siddhartha ;

Avigan, David ;

Craig, Michael ;

Collins, Robert ;

Maris, Michael ;

Kovacsovics, Tibor ;

Goldberg, Stuart ;

Seiter, Karen ;

Hari, Parameswaran ;

Greiner, Jochen ;

Vey, Norbert ;

Recher, Christian ;

Ravandi, Farhad ;

Wang, Eunice S. ;

Vasconcelles, Michael ;

Huebner, Dirk ;

Kantarjian, Hagop M. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2492-2499

[6] A clofarabine-based bridging regimen in patients with relapsed ALL and persistent minimal residual disease (MRD) [J].

Gossai, N. ;

Verneris, M. R. ;

Karras, N. A. ;

Gorman, M. F. ;

Patel, N. J. ;

Burke, M. J. .

BONE MARROW TRANSPLANTATION, 2014, 49 (03) :440-442

[7] A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia [J].

Hijiya, N. ;

Gaynon, P. ;

Barry, E. ;

Silverman, L. ;

Thomson, B. ;

Chu, R. ;

Cooper, T. ;

Kadota, R. ;

Rytting, M. ;

Steinherz, P. ;

Shen, V. ;

Jeha, S. ;

Abichandani, R. ;

Carroll, W. L. .

LEUKEMIA, 2009, 23 (12) :2259-2264

[8] Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia [J].

Hijiya, Nobuko ;

Thomson, Blythe ;

Isakoff, Michael S. ;

Silverman, Lewis B. ;

Steinherz, Peter G. ;

Borowitz, Michael J. ;

Kadota, Richard ;

Cooper, Todd ;

Shen, Violet ;

Dahl, Gary ;

Thottassery, Jaideep V. ;

Jeha, Sima ;

Maloney, Kelly ;

Paul, Jo-Anne ;

Barry, Elly ;

Carroll, William L. ;

Gaynon, Paul S. .

BLOOD, 2011, 118 (23) :6043-6049

[9] Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup [J].

Huguet, Francoise ;

Leguay, Thibaut ;

Raffoux, Emmanuel ;

Rousselot, Philippe ;

Vey, Norbert ;

Pigneux, Arnaud ;

Ifrah, Norbert ;

Dombret, Herve .

LEUKEMIA & LYMPHOMA, 2015, 56 (04) :847-857

[10] Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia [J].

Jeha, S ;

Gaynon, PS ;

Razzouk, BI ;

Franklin, J ;

Kadota, R ;

Shen, V ;

Litchtman-Jones, L ;

Rytting, M ;

Bomgaars, LR ;

Rheingold, S ;

Ritchey, K ;

Albano, E ;

Arceci, RJ ;

Goldman, S ;

Griffin, T ;

Altman, A ;

Gordon, B ;

Steinherz, L ;

Weitman, S ;

Steinherz, P .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) :1917-1923

← 1 2 3 →